Hematology-Oncology 2014 Infographic

December 02, 2014

The American Society of Hematology (ASH) 2014 annual meeting will take place on December 5–9, 2014. As a preview for our BioMedTracker ASH meeting coverage, we provide a graphical overview of epidemiology and the drug development space in hematology-oncology. Several drugs were approved in the last year to treat blood cancers, including the first-in-class drugs Imbruvica (PCYC/JNJ), Zydelig (GILD), and Sylvant (JNJ). Drug candidates in the pipeline today may eventually transform the treatment of ALL, AML, and other blood cancers.<br><br> This infographic also provides a summary of key data presentations for blood cancers at the ASH meeting. Drug candidates with exciting new or updated data include: blinatumomab (AMGN), daratumumab (JNJ), Opdivo (nivolumab; BMY), inotuzumab ozogamacin (PFE), and ABT-199/venetoclax (ABBV).<br><Br> To receive a free copy of this infographic, please fill out the form to the right. <br><br> <font size=1>For our disclosures, please read the <a href="Standards.cfm" target="_blank">BioMedTracker Research Standards</a>.</font>